Erastapex Plus

Quick links to important sections

Erastapex Plus

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Erastapex Plus

Quick Facts

Property Description
Active Ingredient Olmesartan Medoxomil, Hydrochlorothiazide
Form Film-coated tablet (Oral)
Pharmacological Class Antihypertensive Combination
General Purpose Management of high blood pressure (Hypertension)
Origin Synthetic (Chemically synthesized)

Erastapex Plus: Identity and Core Classification

Erastapex Plus is an orally administered, synthetic, prescription medication classified as a fixed-dose combination antihypertensive agent. This proprietary formulation distinguishes itself by providing the benefit of two active compounds in a single film-coated tablet. This combination strategy is often clinically recognized for its potential to improve adherence and efficacy compared to administering the two agents separately.

The medication is generally not intended for initial therapy but is specifically utilized when a patient’s established hypertension remains inadequately controlled by one component alone. Lowering elevated blood pressure is the primary goal, a therapeutic action confirmed across multiple pharmacologic classes.

Composition: Dual Active Ingredients and Classes

The medication contains the two International Nonproprietary Names (INN): Olmesartan Medoxomil and Hydrochlorothiazide. These compounds belong to complementary pharmacological classes that target different pathways related to blood pressure regulation. Olmesartan Medoxomil is categorized as a synthetic Angiotensin II Receptor Blocker (ARB), which works to relax blood vessels.

Hydrochlorothiazide is a Thiazide Diuretic, which assists the body in reducing circulating fluid volume by increasing sodium and water excretion via the kidneys. The combination of these two drug classes is effective for treating certain cases of uncomplicated hypertension.

General Therapeutic Purpose

The general therapeutic purpose of this dual-agent fixed-dose combination is to manage persistent high blood pressure by targeting both vascular resistance and fluid volume. The combined strategy provides comprehensive management when a single agent is insufficient. By balancing the vessel-relaxing action of the ARB with the volume-reducing action of the diuretic, Erastapex Plus is designed to achieve effective, sustained blood pressure lowering.

What side effects are possible with Erastapex Plus?

Possible Side Effects and Safety Information

The regulatory safety profile of Erastapex Plus (Olmesartan Medoxomil/Hydrochlorothiazide) is categorized by the organ system affected and the frequency observed in clinical studies or reported during post-marketing surveillance, strictly as documented by government health authorities.

Adverse reactions are classified into categories such as Common and Rare. Common reactions (occurring in ge 1/100 patients) often include dizziness, headache, fatigue, nasopharyngitis, and diarrhea or nausea (Gastrointestinal Disorders).

System-Organ Classes officially associated with effects include Nervous System Disorders, Vascular Disorders (e.g., hypotension), and Metabolism and Nutrition Disorders, which may involve disturbances like electrolyte imbalances (e.g., hypokalemia) and elevated blood sugar (hyperglycemia) or uric acid (hyperuricemia).

Serious Adverse Reactions and Safety Constraints

Official labeling highlights several serious effects and constraints:

  • Fetal Toxicity: Use during the second and third trimesters of pregnancy is associated with fetal injury or death, making it contraindicated.
  • Renal Safety: The medication is contraindicated in patients with severe renal impairment (creatinine clearance le 30 mL/min) and may be associated with impaired renal function or azotemia.
  • Chronic Effects: Post-marketing reports document rare but serious reactions such as sprue-like enteropathy (severe, chronic diarrhea) and an increased risk of Non-Melanoma Skin Cancer (NMSC) associated with the increasing cumulative dose exposure of the hydrochlorothiazide component.
  • Ocular Effects: Rare but serious Eye Disorders associated with the hydrochlorothiazide component include acute secondary angle-closure glaucoma.

Hypotension (low blood pressure) is a documented concern, particularly in patients who are volume- or salt-depleted, and may occur more readily at the initiation of treatment.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

Overdose with this fixed-dose combination medication is officially documented to be characterized by the exaggeration of its known pharmacological effects. Manifestations may include Symptomatic Hypotension (severe low blood pressure) and changes in heart rhythm, specifically Tachycardia (fast heart rate) or Bradycardia (slow heart rate). Excessive fluid loss from the diuretic component may also lead to clinical signs of Volume Depletion and potentially life-threatening conditions like Severe Electrolyte Imbalance (e.g., Hypokalemia or Hyponatremia) and Acute Renal Failure.

Immediate Actions and Management

Seek immediate medical attention for any suspected overdose. Emergency medical care is required if the affected individual has collapsed, has trouble breathing, or cannot be awakened.

Management is symptomatic and supportive, as no specific antidote is known. Officially described supportive measures for severe hypotension include placing the patient in the supine position and, if necessary, administering an intravenous infusion of normal saline. Hospital monitoring is required, specifically including the close observation of vital signs and laboratory monitoring of serum electrolytes and renal function.

A special regulatory consideration applies to neonates with in utero exposure, who must be closely observed for hypotension, oliguria, and hyperkalemia, which may require intensive supportive measures, including dialysis.

Therapeutic Uses of Erastapex Plus

Erastapex Plus is a fixed-dose combination relevant for managing conditions characterized by periods of heightened symptoms related to systemic imbalance, specifically high blood pressure (hypertension). It contains two components, olmesartan medoxomil and hydrochlorothiazide, that may assist in managing blood pressure.

This therapy is indicated for the treatment of hypertension. The olmesartan medoxomil component is applied in addressing symptoms related to heightened physiological activity, and the hydrochlorothiazide component may assist with managing symptoms related to systemic imbalance. It is applied in clinical settings that involve acute or unstable symptom patterns related to high blood pressure, and is commonly used across conditions presenting with acute episodes. The main therapeutic areas include conditions associated with chronic elevated blood pressure and conditions involving episodic or fluctuating manifestations of high blood pressure.

This therapeutic approach supports patients during episodes of heightened discomfort and assists with maintaining functional stability. Appropriate management of blood pressure contributes to easing the overall symptom load and supports general well-being.

“The combination approach is relevant when supportive symptom management is appropriate, assisting with overall comfort.”

Quick Fact: Support for Symptoms that Create Noticeable Physiological Strain

Eligibility and Restrictions for Use

Who Can and Cannot Use Erastapex Plus?

The eligibility for Erastapex Plus (Olmesartan Medoxomil and Hydrochlorothiazide) is defined by regulatory documents, restricting use to specific populations.

Formal Contraindications (Must Not Use)

Official labeling contraindicates use in patients with:

  • Anuria or Severe Hepatic Impairment.
  • Known Hypersensitivity to the active ingredients or to sulfonamide-derived drugs.
  • Pregnancy in the second or third trimester; the medicine must be discontinued immediately if pregnancy is detected. Use is also not recommended in the first trimester or while breastfeeding.

Age and Condition Restrictions

The medicine is approved for use only in adults with hypertension. Use is not recommended for pediatric patients (under 18 years) as safety and efficacy have not been established.

Conditional use or close monitoring is required for patients with moderate renal or hepatic impairment, or Systemic Lupus Erythematosus (SLE). Therapy must not be initiated in patients with uncorrected volume or salt depletion or refractory electrolyte imbalances.

What should I know about interactions with other medicines?

The official regulatory profile for Erastapex Plus documents specific interaction patterns that necessitate restrictions or procedural requirements for co-administration with certain medicinal products and substances. These interactions are classified based on the mechanism by which they affect the drug's components or the patient's physiological state.

Contraindicated and Restricted Combinations

Classification Interacting Substance Official Interaction Statement
Contraindicated Aliskiren Co-administration is prohibited in patients with Diabetes Mellitus or Renal Impairment (GFR < 60 mL/min/1.73 m^2) due to increased risks of hyperkalemia and renal dysfunction.
Significant Risk Lithium The combination carries a documented high risk of Lithium toxicity due to reduced renal clearance of lithium.

Pharmacodynamic and Absorption Interactions

Co-administration with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including selective COX-2 inhibitors, may result in the reduction of antihypertensive and diuretic effects and increases the regulatory-documented risk of worsening renal function.

Agents that increase serum potassium, such as potassium-sparing diuretics or potassium supplements, heighten the risk of hyperkalemia (high blood potassium).

Colesevelam Hydrochloride reduces the systemic exposure of Olmesartan and necessitates a mandatory separation of administration, requiring that Erastapex Plus be taken at least 4 hours prior to the Colesevelam dose. Similarly, Cholestyramine and Colestipol resins reduce the absorption of the Hydrochlorothiazide component. Finally, concurrent consumption of alcohol may potentiate orthostatic hypotension.

Mechanism of Action

Erastapex Plus modulates systemic function through a dual mechanism involving the renin-angiotensin-aldosterone system (RAAS) and renal electrolyte transport.

Olmesartan medoxomil acts as a prodrug, undergoing rapid hydrolysis to the active compound, olmesartan. Olmesartan functions as a selective antagonist of the Angiotensin II Type 1 ( AT1) receptor located in vascular smooth muscle and the adrenal cortex. By competitively blocking AT1 receptors, the compound inhibits the downstream effects of Angiotensin II, primarily preventing arteriolar vasoconstriction and suppressing the release of aldosterone. The systemic consequence is a modulation of peripheral resistance.

Hydrochlorothiazide is a thiazide diuretic that acts on the renal distal convoluted tubule. It inhibits the Na^+/ Cl^- cotransporter protein, which reduces the reabsorption of sodium and chloride ions. This inhibition increases the fractional excretion of Na^+ and water, thereby reducing extracellular fluid volume.

Dosage and Administration Information

Erastapex Plus is a fixed-dose combination delivered exclusively as a film-coated tablet for oral ingestion. Its administration follows a defined protocol focused on individualized dosage and consistent timing.

Dosing Schedule and Frequency

The medication is taken once daily (QD). The standard starting dose is determined by the patient’s prior response to single-agent therapy, utilizing strengths such as 20 mg/12.5 mg or 40 mg/12.5 mg (Olmesartan Medoxomil/Hydrochlorothiazide). The maximum recommended daily dose is 40 mg/25 mg. This regimen is intended for long-term management of high blood pressure, and dosage adjustment requires a minimum interval of 2 to 4 weeks to fully assess the efficacy of the current dose before titration.


Administration Conditions

The tablet may be taken with or without food. A specific procedural condition exists if the patient is concurrently taking the bile acid sequestrant colesevelam: Erastapex Plus must be administered at least 4 hours before the colesevelam dose to ensure proper absorption of the olmesartan component.

For general procedural steps, if a dose is missed, the instruction is to take it as soon as possible, but to skip the missed dose if it is almost time for the next scheduled dose, thereby prohibiting the doubling of doses. Furthermore, no initial dosage adjustment is recommended for older adult patients solely based on age. These explicit instructions define the standardized procedural structure for the use of the drug.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Efficacy in Chronic Migraine

Research evaluated whether the investigational drug influenced symptoms of severe chronic migraine in adult participants who had previously not responded to prophylactic treatments.

  • Primary Outcome: Studies focused on measuring the average change in monthly migraine days.
  • Attack Frequency and Severity: Research examined the potential influence on the frequency or severity of attacks.
  • Long-Term Research: Studies reported findings regarding the change in attack frequency over time across various trials.

Combination Therapy Research

Some research examined the data potentially supporting the use of the drug alongside standard prophylactic treatments. This finding prompted researchers to examine whether the continued use of other prophylactic treatments was a factor in the outcome.

  • Research explored whether the combination was associated with a difference in patient response rates compared to monotherapy.

Safety and Tolerability Profile

Researchers in clinical trials evaluated the drug’s use in randomized, placebo-controlled settings. These findings pertain to studies involving adults receiving the treatment for up to 12 weeks.

  • Common Side Effects: Common side effects reported include injection site reactions, constipation, and muscle spasms.
  • Rare Adverse Events: Researchers documented rare adverse events, including hypertension and hypersensitivity reactions.

Patient-Reported Outcomes (PROs)

Research explored the timeframe for potential changes in patient-reported outcomes related to quality of life measures, such as changes in the ability to perform daily activities.

Comparative Effectiveness

Studies examined differences in outcomes between this treatment and other CGRP inhibitors. These studies primarily focused on head-to-head tolerability and patient retention rates within the trial cohorts.

Frequently Asked Questions (FAQ)

Common questions about Erastapex Plus (FAQ)

Q: What is the main difference between Erastapex Plus and a regular Erastapex tablet?

A: According to official product information, Erastapex Plus is a fixed-dose combination containing two active ingredients: Olmesartan, which is an Angiotensin II Receptor Blocker (ARB), and Hydrochlorothiazide, which is a diuretic. A regular Erastapex tablet would typically contain only Olmesartan, the single active ingredient. The 'Plus' signifies the addition of a second compound to the formulation.

Q: How does the 'Plus' part of the name change what the drug does?

A: The 'Plus' component is Hydrochlorothiazide, which acts as a diuretic, sometimes called a 'water pill.' This adds a second mechanism of action that helps the body remove excess salt and water through the kidneys. This complements the other ingredient, which works to relax blood vessels, resulting in a dual approach to lowering blood pressure.

Q: What are the known risks of stopping Erastapex Plus suddenly?

A: Stopping this medication suddenly is often advised against in product information without professional guidance. Discontinuation may cause blood pressure to rise suddenly (a 'rebound spike'). This rise could potentially increase the risk of serious cardiovascular events, such as a heart attack or stroke.

Q: Is it true that Erastapex Plus can interact with certain common over-the-counter pain relievers?

A: Official information indicates that the medication can interact with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which include common over-the-counter pain relievers. This interaction may reduce the blood pressure-lowering effect of Erastapex Plus. It is also described as increasing the regulatory-documented risk of worsening kidney function.

Q: What should a person do if they miss a dose of Erastapex Plus?

A: According to the administration instructions, official guidance is generally to take the missed dose as soon as it is noticed. However, if it is almost time for the next regularly scheduled dose, the missed dose is generally skipped to prevent doubling up. Product information advises against taking two doses simultaneously to catch up.

Q: How does the drug's use condition change if the person has kidney or liver problems?

A: The medication is officially contraindicated in patients with severe liver or severe kidney impairment. For patients who have mild to moderate kidney or liver impairment, conditional use is defined by regulatory documents, which often requires close professional monitoring. A lower maximum daily dose may also be considered by a healthcare provider.

Q: How soon after stopping Erastapex Plus does it leave the body?

A: The body eliminates the Olmesartan component with a half-life of approximately 13 hours, and the Hydrochlorothiazide component with a half-life between 5.6 and 14.4 hours. Pharmacokinetic principles suggest that drugs are substantially eliminated after approximately five half-lives.

Q: What type of monitoring (e.g., blood tests) is sometimes needed while taking Erastapex Plus?

A: Because this medication affects electrolyte balance and metabolism, official labeling recommends periodic monitoring with blood tests. These tests typically check the levels of serum electrolytes, such as potassium and sodium, as well as kidney function markers, uric acid, and blood glucose.

Q: Can consuming caffeine or alcohol affect how Erastapex Plus works?

A: Official patient counseling materials state that consuming alcohol may increase the risk of low blood pressure (hypotension) and associated side effects like dizziness. While there is no formal warning against caffeine, general guidance for blood pressure management often advises monitoring or moderating stimulant intake.

Q: What should I do if my tablet of Erastapex Plus looks slightly different than usual?

A: The product information advises that the medication should be stored in its original container, away from excess heat and moisture, to ensure drug stability. If the appearance of the tablet is noticeably different, or if storage is suspected to be improper, official patient information advises consulting with a pharmacist.

Q: Does Erastapex Plus have a generic version available?

A: Yes, the active ingredients in this combination medication are available in generic form. These generic products are listed under their chemical names: Olmesartan Medoxomil and Hydrochlorothiazide.

Q: Can Erastapex Plus be used for conditions other than those listed in the official uses?

A: According to regulatory documents, the medication is officially indicated only for the treatment of hypertension (high blood pressure). It is not recommended for use to treat any other medical condition unless the prescribing professional directs it.

Q: Are there any side effects of Erastapex Plus that are reported as very rare?

A: Rare side effects have been reported during post-marketing surveillance, including severe, long-term diarrhea leading to substantial weight loss (sprue-like enteropathy). Other rare serious effects documented include a specific eye disorder called acute secondary angle-closure glaucoma.

Q: Is a headache a common side effect when starting Erastapex Plus?

A: Yes, headache is listed as a common side effect observed in clinical trials. It is often reported to occur upon treatment initiation or after an increase in dosage.

Q: Do the side effects of Erastapex Plus usually go away after the first few weeks?

A: Official information indicates that the full blood pressure-lowering effects are attained within two to four weeks. While many common initial side effects may lessen as the body adjusts, regulatory product information does not explicitly guarantee that all side effects will resolve completely after a few weeks.

Q: Are there known interactions between Erastapex Plus and herbal supplements or vitamins?

A: The medication has a documented risk of interaction with products that increase serum potassium, which includes some potassium supplements and salt substitutes. Patients are generally advised in counseling materials to inform their healthcare provider about all vitamins, minerals, and herbal products being used.

Q: Does Erastapex Plus have known food interactions to be aware of?

A: The tablet may be taken with or without food. Although there are no formal food-specific contraindications, patients are advised to discuss their intake of electrolytes with their healthcare provider, especially foods high in potassium or salt substitutes containing potassium.

Q: Can Erastapex Plus affect a person's ability to drive or operate heavy machinery?

A: Official patient counseling materials state that the medication can cause dizziness, lightheadedness, or tiredness, especially at the start of treatment. Patients are advised to use caution when driving or operating heavy machinery until they know how the drug affects them.

Q: What does the research evidence say about the long-term use of Erastapex Plus?

A: The drug is intended for the long-term management of high blood pressure, as lowering blood pressure over time reduces the risk of serious cardiovascular events. Regarding long-term safety, official labeling notes an increased risk of Non-Melanoma Skin Cancer (NMSC) with increasing cumulative dose exposure to the hydrochlorothiazide component.

Q: If I have mild symptoms, is Erastapex Plus still recommended in official guidelines?

A: Regulatory documents indicate that the medication is generally not intended for the initial therapy of hypertension. It is typically prescribed for adult patients whose blood pressure is not adequately controlled by one of the single active components alone.

Q: Is there a high chance of becoming physically dependent on Erastapex Plus?

A: The active ingredients in this medication are not classified as controlled substances by the U.S. Drug Enforcement Administration. Stopping the drug suddenly is not recommended, not due to dependence, but to prevent a rebound spike in blood pressure.

Q: Can I crush or split my Erastapex Plus tablets to make them easier to swallow?

A: The tablets are film-coated and non-scored according to the product description. Unless specifically advised otherwise by a healthcare professional, they are generally intended to be swallowed whole and should not be split, chewed, or crushed.

Q: Is Erastapex Plus known to cause weight gain or loss?

A: A rare but serious side effect reported during post-marketing use is severe, chronic diarrhea (sprue-like enteropathy), which can lead to substantial weight loss. Initial changes in weight may also be related to the diuretic component's intended effect on fluid volume.

Q: Why do some people experience initial sleep changes when starting Erastapex Plus?

A: The hydrochlorothiazide component is a diuretic, which increases the frequency of urination. Patient counseling materials advise taking the medication earlier in the day to prevent nighttime waking and potential sleep disturbance associated with increased urination.

Q: Is it true that Erastapex Plus has a Boxed Warning (Black Box Warning)?

A: Yes, the official labeling contains a Boxed Warning. This warning is for Fetal Toxicity, indicating that drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus when used during the second and third trimesters of pregnancy.

Q: What is the mechanism of action of Erastapex Plus in simple terms?

A: According to authorized patient information, the medication works in two complementary ways. One ingredient helps relax blood vessels, and the other ingredient is a diuretic, often called a water pill. The combined effect of vessel relaxation and reduced fluid volume helps to lower blood pressure.

Q: If a dose feels like it is not working, what does the official guidance suggest?

A: Official guidance states that the full blood pressure-lowering effect is attained within two to four weeks after a dose change. If you feel the dose is not working, it is advised to wait this interval before your healthcare provider considers adjusting the dosage.

Q: Are there any specific lifestyle changes mentioned in the product information that may complement Erastapex Plus?

A: Patient information mentions complementing the medication with lifestyle adjustments. These include discussing any low-salt dietary restrictions with a healthcare provider and maintaining adequate hydration, particularly in hot weather or during physical activity.

Q: Are there any common recreational substances that have known interactions with Erastapex Plus?

A: Patient counseling materials advise speaking with a healthcare professional before using alcohol, marijuana, or other forms of cannabis. These substances may worsen the drug's effects, such as dizziness or low blood pressure.

How should Erastapex Plus be stored and disposed of?

How to Store and Dispose of Erastapex Plus

The storage of Erastapex Plus (olmesartan medoxomil and hydrochlorothiazide) must adhere strictly to labeled regulatory requirements to maintain drug stability.


Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, typically between 20°C and 25°C (68°F and 77°F).
Protection Keep away from excess heat, moisture, and direct light; must be kept from freezing.
Container Store in the original container and ensure it remains tightly closed to protect the tablets.
Child Safety Mandatory to store the medication out of the sight and reach of children.

Disposal Instructions

Expired or unused Erastapex Plus must be managed responsibly. Patients are instructed to not keep outdated medicine and to ask a healthcare professional or pharmacist for guidance on how to properly discard any unused product according to local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Erastapex Plus found in:

A-Z Index: